indicate the propensity for a medication to cause potentially fatal hepatotoxicity. 10 The use of either UFH or LMWH in a patient that subsequently develops transaminitis should prompt consideration that these agents may be the cause, especially if no risk factors for, or a history of hepatic disease, exists. In this article, we present a case of probable heparin-induced hepatotoxicity after the subcutaneous administration of prophylactic doses UFH in a 70-year-old male. A review of literature including the proposed mechanisms behind, risk factors for, and other reports of heparin-induced hepatotoxicity is also discussed.
Case Report
The patient is a 70-year-old, 66-kg, Caucasian male, with a past medical history of vestibulopathy of unknown origin, benign prostatic hyperplasia, hypertension, gastroesophageal reflux disorder, and hypercholesterolemia. He had no history of prior liver dysfunction. His social history included smoking 1 pack of cigarettes per day for the last 50 years, and he denied use of any alcohol or illicit drugs. He had no known drug allergies, and a complete list of his home medications, including over-the-counter medications and herbal products, and inpatient medications can be found in Table 1 .
The patient presented to the emergency room at our institution with a chief complaint of lightheadedness without loss of consciousness for approximately 30 minutes. His lightheadedness was accompanied by significant nausea and facial pallor, without diaphoresis. Vital signs indicated a blood pressure of 135/86 mm Hg, a pulse rate of 91 beats/ min, a respiratory rate of 16 breaths/min, and a temperature of 97.5°F. Basic metabolic panel, complete blood count, and liver function tests were all within normal limits. Review of systems and physical examination were relatively unremarkable. Abdominal examination indicated that his abdomen was soft, nontender, and nondistended, with no organomegaly, and normoactive bowel sounds were present.
The patient was admitted and diagnosed with presyncope, secondary to dehydration, and new-onset congestive heart failure indicated by a reduced left ventricular ejection fraction of 32% on echocardiogram. Unfractionated heparin was initiated for deep vein thrombosis prophylaxis at a dose of 5000 units subcutaneously every 8 hours, in addition to aspirin 81 mg daily. His course of hospitalization was relatively uncomplicated; however, on day 2 of hospitalization, his liver enzymes were found to be slightly elevated. By day 4 of hospitalization, his liver enzymes were markedly elevated: AST and ALT were greater than 5, and 9 times the ULN, respectively. Elevations in total bilirubin and alkaline phosphatase (ALP) were seen as well ( Table 2) .
The patient's coagulation profile (ie, activated partial thromboplastin time, prothrombin time, and international normalized ratio), in addition to his serum albumin and hemoglobin/hematocrit, remained within normal limits. UFH was discontinued on day 4 and the patient was subsequently discharged the same day. He was seen as an outpatient 10 days later where AST and total bilirubin had returned to within normal limits, while ALT and ALP declined from their peak values but remained slightly elevated ( Table 2 ). The patient was not rechallenged with any form of heparin after discharge.
Discussion
Since the first case of hepatotoxicity attributed to heparin was reported in 1975, 12 it has subsequently been described as a class effect, occurring with the administration of LMWH as well. Historically, transaminitis was defined as any elevation in transaminases greater than the ULN. As a result of heparin therapy, it was originally thought to occur in upward of 90% and 30% of those receiving UFH 6,13 and LMWH, 8 respectively. Newer literature suggest that hepatotoxicity, further specified as serum transaminase concentrations greater than 3 times the ULN, as a result of UFH is thought to occur much less frequently in only 5% of patients.
7-9 These rates are not reflected in the current prescribing information for heparin sodium. 3 In patients using LMWH, hepatotoxicity is thought to occur in 5% to 10% of patients, with higher rates associated with dalteparin use versus enoxaparin. 14, 15 Tinzaparin, removed from the US market in 2011, was associated with the highest rates of hepatotoxicity at 13.3%. The most common manifestations of heparin-induced hepatotoxicity are elevations in AST and ALT. Elevations in ALP have not been widely reported and are considered to be relatively rare. 8, 13, [17] [18] [19] Elevations in hepatic transaminases are typically seen after 4 to 5 days of heparin use, 8, 17, 20 with enzymes reaching their peak after approximately 7 days. 9, 19, 21 Transaminase values typically return to normal within 2 weeks after the discontinuation of heparin, without the development of any sequalae, 8, 9 suggesting that they may be clinically insignificant. Elevations in bilirubin are rarely reported and not typically seen with increases in hepatic transaminases. 9, 13, 17 Elucidating the mechanism(s) behind heparin-induced hepatotoxicity has been the subject of several studies, with purported mechanisms including the modification of hepatocellular membranes, 22 direct toxicity of heparin on the hepatocytes, 23 and immune-mediated hypersensitivity. 22 , 23 Harrill et al 7 evaluated the potential mechanisms behind heparin-induced hepatotoxicity in a Phase I randomized study. They observed a rise in high mobility group box 1 protein (HMGB1), a known damage-associated molecular pattern, after the administration of heparins. HMGB1 is released from necrotic cells, which subsequently binds to Toll-like receptors-triggering an innate immune response. 24 HMGB1 protein peaked 2 days after the last dose of heparin, suggesting an indirect effect on hepatocytes. Additionally, they noted an absence of kerratin 18 fragments, which are markers of apoptosis. The authors concluded that heparins are able to induce a transient hepatocyte necrosis and subsequent activation of the innate immune system. Despite ongoing research, the exact mechanisms behind heparin-induced hepatotoxicity remains unknown.
Several risk factors for the development of heparininduced hepatotoxicity have been identified. Dukes et al 25 concluded that male gender and higher baseline liver enzymes were associated with the development of heparininduced hepatotoxicity, while Guevara et al 23 concluded that male gender, advanced age, and total dose of UFH were predictors. While previous reports of heparin-induced hepatotoxicity have suggested a dose-dependent effect, 13, 20, 23 several studies have not substantiated these claims 21, 25, 26 ; whether or not this is truly a dose-dependent effect remains controversial.
Our patient presented with probable UFH-induced hepatotoxicity with a score of 7 using the Naranjo algorithim 27 (Table 3) . Although the patient was also initiated on lowdose aspirin during his hospital stay, it was not believed to be a cause of the abnormalities observed. Aspirin-induced hepatotoxicity usually occurs with long-term, high-dose (>100 mg/kg) therapy, and may be associated with elevations in ALT, with bilirubin elevations typically absent. 28 Only one of the patients home medications, atorvastatin, had the potential to cause liver damage; however, the patient was stable on this medication for more than 1 year without any abnormalities in liver function. UFH was suspected as the culprit given that the elevations in transaminases and bilirubin resolved following discontinuation of UFH, while atorvastatin and aspirin were both continued. Risk factors in our patient include male gender and his advanced age. No sequelae were observed following the discontinuation of UFH in our patient.
Compared with other published case reports of heparininduced hepatotoxicity (Table 4) , there were some differences seen with our patient. The first being that in other published reports, patients were being treated with therapeutic doses of either UFH or LMWH. Our patient was receiving prophylactic doses of UFH, something that has not been reported in the literature. Second, our patient also had significant elevations in his bilirubin and ALP, something not seen in other published case reports. Although Levinson et al 29 reported elevations in bilirubin and ALP with dalteparin therapy, this patient was being treated with therapeutic doses for 42 days. The rise in our patient's liver enzymes were apparent by day 2 of UFH use. Other published reports have seen rapid elevations in liver enzymes as well. 30, 31 This may suggest that heparin-induced hepatotoxicity may occur more rapidly than 4 to 5 days, which has been previously described. 
Conclusion
A 70-year-old man developed hepatotoxicity secondary to deep vein thrombosis prophylaxis with UFH. This case is unique, given the magnitude of the elevations in his AST, ALT, and ALP, in addition to bilirubin. Although potentially clinically insignificant, given their widespread use, it is important for clinicians to consider heparins, even administered prophylactically, in their differential as a potential cause of hepatotoxicity especially in patients without underlying hepatic disease.
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